Patents by Inventor Wai-si Eng

Wai-si Eng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds as neurokinin-1 receptor antagonists and uses thereof
    Patent number: 11905247
    Abstract: The present invention relates compounds of Formula (A) as NK-1 receptor antagonists, as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses as modulators of dysfunctional glutamate transmission. The present invention also relates to the uses of the compounds or pharmaceutical compositions in treating or preventing certain disorders and diseases which relate to NK-1 receptor in humans. More specifically, the compounds and/or pharmaceutical compositions of the present invention are believed to potentially offer therapeutic benefits to patients who suffer, among others, chemotherapy-induced nausea and vomit (CINV) and/or post-operative nausea and vomit (PONV).
    Type: Grant
    Filed: September 15, 2021
    Date of Patent: February 20, 2024
    Assignee: XWPHARMA LTD.
    Inventors: Jia-Ning Xiang, Xuesong Xu, Yi Feng, Xianbo Liu, Wai-Si Eng
  • KETAMINE DERIVATIVES AND COMPOSITIONS THEREOF
    Publication number: 20220411365
    Abstract: Ketamine derivatives and pharmaceutical compositions thereof are disclosed. When administered orally the ketamine derivatives provide increased bioavailability of ketamine in the systemic circulation. The ketamine derivatives can be used to treat neurological diseases, psychological diseases and pain.
    Type: Application
    Filed: August 1, 2022
    Publication date: December 29, 2022
    Inventors: JIA-NING XIANG, XUESONG XU, HAO-WEI SHIH, WAI-SI ENG
  • COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF
    Publication number: 20220380339
    Abstract: The present invention relates compounds of Formula (A) as 113R antagonists, as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses as modulators of Histamine 3 Receptor (H3R) functions. The present invention also relates to the uses of the compounds or pharmaceutical compositions in treating or preventing certain disorders and diseases which relate to H3R functions in humans.
    Type: Application
    Filed: July 18, 2022
    Publication date: December 1, 2022
    Inventors: JIA-NING XIANG, XUESONG XU, YI FENG, WAI-SI ENG
  • Ketamine derivatives and compositions thereof
    Patent number: 11440874
    Abstract: Ketamine derivatives and pharmaceutical compositions thereof are disclosed. When administered orally the ketamine derivatives provide increased bioavailability of ketamine in the systemic circulation. The ketamine derivatives can be used to treat neurological diseases, psychological diseases and pain.
    Type: Grant
    Filed: October 12, 2020
    Date of Patent: September 13, 2022
    Assignee: XWPHARMA LTD.
    Inventors: Jia-Ning Xiang, Xuesong Xu, Hao-Wei Shih, Wai-Si Eng
  • Compounds as neuronal histamine receptor-3 antagonists and uses thereof
    Patent number: 11420955
    Abstract: The present invention relates compounds of Formula (A) as H3R antagonists, as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses as modulators of Histamine 3 Receptor (H3R) functions. The present invention also relates to the uses of the compounds or pharmaceutical compositions in treating or preventing certain disorders and diseases which relate to H3R functions in humans.
    Type: Grant
    Filed: March 5, 2021
    Date of Patent: August 23, 2022
    Assignee: XWPHARMA LTD.
    Inventors: Jia-Ning Xiang, Xuesong Xu, Yi Feng, Wai-Si Eng
  • COMPOUNDS AS NEUROKININ-1 RECEPTOR ANTAGONISTS AND USES THEREOF
    Publication number: 20220002246
    Abstract: The present invention relates compounds of Formula (A) as NK-1 receptor antagonists, as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses as modulators of dysfunctional glutamate transmission. The present invention also relates to the uses of the compounds or pharmaceutical compositions in treating or preventing certain disorders and diseases which relate to NK-1 receptor in humans. More specifically, the compounds and/or pharmaceutical compositions of the present invention are believed to potentially offer therapeutic benefits to patients who suffer, among others, chemotherapy-induced nausea and vomit (CINV) and/or post-operative nausea and vomit (PONV).
    Type: Application
    Filed: September 15, 2021
    Publication date: January 6, 2022
    Inventors: JIA-NING XIANG, XUESONG XU, YI FENG, XIANBO LIU, WAI-SI ENG
  • Compounds as neurokinin-1 receptor antagonists and uses thereof
    Patent number: 11149006
    Abstract: The present invention relates compounds of Formula (A) as NK-1 receptor antagonists, as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses as modulators of dysfunctional glutamate transmission. The present invention also relates to the uses of the compounds or pharmaceutical compositions in treating or preventing certain disorders and diseases which relate to NK-1 receptor in humans. More specifically, the compounds and/or pharmaceutical compositions of the present invention are believed to potentially offer therapeutic benefits to patients who suffer, among others, chemotherapy-induced nausea and vomit (CINV) and/or post-operative nausea and vomit (PONV).
    Type: Grant
    Filed: March 6, 2020
    Date of Patent: October 19, 2021
    Assignee: XWPHARMA LTD.
    Inventors: Jia-Ning Xiang, Xuesong Xu, Yi Feng, Xianbo Liu, Wai-Si Eng
  • COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF
    Publication number: 20210188808
    Abstract: The present invention relates compounds of Formula (A) as H3R antagonists, as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses as modulators of Histamine 3 Receptor (H3R) functions. The present invention also relates to the uses of the compounds or pharmaceutical compositions in treating or preventing certain disorders and diseases which relate to H3R functions in humans.
    Type: Application
    Filed: March 5, 2021
    Publication date: June 24, 2021
    Inventors: JIA-NING XIANG, XUESONG XU, YI FENG, WAI-SI ENG
  • Compounds as neuronal histamine receptor-3 antagonists and uses thereof
    Patent number: 10968202
    Abstract: The present invention relates compounds of Formula (A) as H3R antagonists, as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses as modulators of Histamine 3 Receptor (H3R) functions. The present invention also relates to the uses of the compounds or pharmaceutical compositions in treating or preventing certain disorders and diseases which relate to H3R functions in humans.
    Type: Grant
    Filed: June 23, 2020
    Date of Patent: April 6, 2021
    Assignee: XW LABORATORIES INC.
    Inventors: Jia-Ning Xiang, Xuesong Xu, Yi Feng, Wai-Si Eng
  • KETAMINE DERIVATIVES AND COMPOSITIONS THEREOF
    Publication number: 20210032199
    Abstract: Ketamine derivatives and pharmaceutical compositions thereof are disclosed. When administered orally the ketamine derivatives provide increased bioavailability of ketamine in the systemic circulation. The ketamine derivatives can be used to treat neurological diseases, psychological diseases and pain.
    Type: Application
    Filed: October 12, 2020
    Publication date: February 4, 2021
    Applicant: XW LABORATORIES INC.
    Inventors: JIA-NING XIANG, XUESONG XU, HAO-WEI SHIH, WAI-SI ENG
  • COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF
    Publication number: 20200369645
    Abstract: The present invention relates compounds of Formula (A) as H3R antagonists, as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses as modulators of Histamine 3 Receptor (H3R) functions. The present invention also relates to the uses of the compounds or pharmaceutical compositions in treating or preventing certain disorders and diseases which relate to H3R functions in humans.
    Type: Application
    Filed: June 23, 2020
    Publication date: November 26, 2020
    Inventors: JIA-NING XIANG, XUESONG XU, YI FENG, WAI-SI ENG
  • Ketamine derivatives and compositions thereof
    Patent number: 10836714
    Abstract: Ketamine derivatives and pharmaceutical compositions thereof are disclosed. When administered orally the ketamine derivatives provide increased bioavailability of ketamine in the systemic circulation. The ketamine derivatives can be used to treat neurological diseases, psychological diseases and pain.
    Type: Grant
    Filed: April 2, 2020
    Date of Patent: November 17, 2020
    Assignee: XW LABORATORIES INC.
    Inventors: Jia-Ning Xiang, Xuesong Xu, Hao-Wei Shih, Wai-Si Eng
  • Compounds as neuronal histamine receptor-3 antagonists and uses thereof
    Patent number: 10730853
    Abstract: The present invention relates compounds of Formula (A) as H3R antagonists, as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses as modulators of Histamine 3 Receptor (H3R) functions. The present invention also relates to the uses of the compounds or pharmaceutical compositions in treating or preventing certain disorders and diseases which relate to H3R functions in humans.
    Type: Grant
    Filed: February 18, 2020
    Date of Patent: August 4, 2020
    Assignee: XW LABORATORIES INC.
    Inventors: Jia-Ning Xiang, Xuesong Xu, Yi Feng, Wai-Si Eng
  • COMPOUNDS AS NEUROKININ-1 RECEPTOR ANTAGONISTS AND USES THEREOF
    Publication number: 20200239416
    Abstract: The present invention relates compounds of Formula (A) as NK-1 receptor antagonists, as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses as modulators of dysfunctional glutamate transmission. The present invention also relates to the uses of the compounds or pharmaceutical compositions in treating or preventing certain disorders and diseases which relate to NK-1 receptor in humans. More specifically, the compounds and/or pharmaceutical compositions of the present invention are believed to potentially offer therapeutic benefits to patients who suffer, among others, chemotherapy-induced nausea and vomit (CINV) and/or post-operative nausea and vomit (PONV).
    Type: Application
    Filed: March 6, 2020
    Publication date: July 30, 2020
    Inventors: JIA-NING XIANG, XUESONG XU, YI FENG, XIANBO LIU, WAI-SI ENG
  • KETAMINE DERIVATIVES AND COMPOSITIONS THEREOF
    Publication number: 20200231540
    Abstract: Ketamine derivatives and pharmaceutical compositions thereof are disclosed. When administered orally the ketamine derivatives provide increased bioavailability of ketamine in the systemic circulation. The ketamine derivatives can be used to treat neurological diseases, psychological diseases and pain.
    Type: Application
    Filed: April 2, 2020
    Publication date: July 23, 2020
    Applicant: XW LABORATORIES INC.
    Inventors: JIA-NING XIANG, XUESONG XU, HAO-WEI SHIH, WAI-SI ENG
  • Ketamine derivatives and compositions thereof
    Patent number: 10683262
    Abstract: Ketamine derivatives and pharmaceutical compositions thereof are disclosed. When administered orally the ketamine derivatives provide increased bioavailability of ketamine in the systemic circulation. The ketamine derivatives can be used to treat neurological diseases, psychological diseases and pain.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: June 16, 2020
    Assignee: XW LABORATORIES INC.
    Inventors: Jia-Ning Xiang, Xuesong Xu, Hao-Wei Shih, Wai-si Eng
  • COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF
    Publication number: 20200181112
    Abstract: The present invention relates compounds of Formula (A) as H3R antagonists, as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses as modulators of Histamine 3 Receptor (H3R) functions. The present invention also relates to the uses of the compounds or pharmaceutical compositions in treating or preventing certain disorders and diseases which relate to H3R functions in humans.
    Type: Application
    Filed: February 18, 2020
    Publication date: June 11, 2020
    Inventors: JIA-NING XIANG, XUESONG XU, YI FENG, WAI-SI ENG
  • Compounds as neuronal histamine receptor-3 antagonists and uses thereof
    Patent number: 10618886
    Abstract: The present invention relates compounds of Formula (A) as H3R antagonists, as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses as modulators of Histamine 3 Receptor (H3R) functions. The present invention also relates to the uses of the compounds or pharmaceutical compositions in treating or preventing certain disorders and diseases which relate to H3R functions in humans.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: April 14, 2020
    Assignee: XW LABORATORIES INC.
    Inventors: Jia-Ning Xiang, Xuesong Xu, Yi Feng, Wai-Si Eng
  • COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF
    Publication number: 20200102289
    Abstract: The present invention relates compounds of Formula (A) as H3R antagonists, as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses as modulators of Histamine 3 Receptor (H3R) functions. The present invention also relates to the uses of the compounds or pharmaceutical compositions in treating or preventing certain disorders and diseases which relate to H3R functions in humans.
    Type: Application
    Filed: September 30, 2019
    Publication date: April 2, 2020
    Inventors: JIA-NING XIANG, XUESONG XU, YI FENG, WAI-SI ENG
  • KETAMINE DERIVATIVES AND COMPOSITIONS THEREOF
    Publication number: 20190322618
    Abstract: Ketamine derivatives and pharmaceutical compositions thereof are disclosed. When administered orally the ketamine derivatives provide increased bioavailability of ketamine in the systemic circulation. The ketamine derivatives can be used to treat neurological diseases, psychological diseases and pain.
    Type: Application
    Filed: July 3, 2019
    Publication date: October 24, 2019
    Inventors: Jia-Ning Xiang, Xuesong Xu, Hao-Wei Shih, Wai-si Eng